Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26539306 | 1.00 | CYP1A2 (0.58) | CYP1A2AAK1CNR2PIK3CAPIK3CD | |
| SCHEMBL26539294 | 1.00 | CYP1A2 (0.58) | CYP1A2AAK1CNR2PIK3CAPIK3CD | |
| SCHEMBL20204065 | 0.93 | CYP1A2 (0.67) | CYP1A2 | |
| SCHEMBL22744865 | 0.93 | CYP1A2 (0.67) | CYP1A2 | |
| SCHEMBL22744842 | 0.93 | CYP1A2 (0.67) | CYP1A2 | |
| SCHEMBL23454353 | 0.91 | CYP1A2 (0.55) | CYP1A2AAK1PIK3CA | |
| SCHEMBL23454314 | 0.91 | CYP1A2 (0.55) | CYP1A2AAK1PIK3CA | |
| SCHEMBL23454317 | 0.91 | CYP1A2 (0.55) | CYP1A2AAK1PIK3CA | |
| SCHEMBL23116005 | 0.91 | CYP1A2 (0.57) | CYP1A2CNR2PIK3CAPIK3CDPDGFRA | |
| SCHEMBL23116013 | 0.91 | CYP1A2 (0.57) | CYP1A2CNR2PIK3CAPIK3CDPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885AAK1 3892/4885CNR2 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.